A finance report highlights Ambrosia and Syneron moving toward the clinic with nine-digit Series B rounds, positioning the funding to support late preclinical or early clinical execution. The report also points to other capital-market catalysts and corporate finance updates affecting the biopharma ecosystem. For biotech investors and operators, Series B rounds are often a pivot point where platform validation meets translational execution, including trial site buildout, CMC scaling, and first-in-human readiness. The specific mention of “toward the clinic” signals funding momentum for programs exiting discovery. The broader mix of items in the finance roundup reflects continued activity across IPO planning, fund launches, and follow-on financing in the sector.